NGS-based RNA-sequencing Market Size & Growth Forecast 2027–2036, By Segments (Product & Service, Application, End Use, Workflow), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
NGS-based RNA-sequencing Market size was estimated at USD 5.16 billion in 2026 and is projected to grow at a 17.99% CAGR from 2027 to 2036, crossing USD 26.98 billion by 2036. The industry revenue for 2027 is assessed at USD 5.96 billion.
Get more details on this report
Request Free Sample ReportNGS-based RNA-sequencing Market Intelligence Snapshot
Regional Market Dynamics
- North America held 51.06% of the market in 2026, supported by advanced sequencing infrastructure, extensive genomics research, and strong adoption across pharmaceutical, academic, and healthcare applications.
- Growing biotechnology research, government-supported genomics initiatives, and improved sequencing infrastructure are expanding RNA-sequencing applications in drug discovery, cancer research, biomarker identification, and precision medicine across Asia Pacific.
Segment Momentum
- Consumables accounted for 59.86% of the product and service segment in 2026, reflecting recurring demand for reagents, library preparation materials, and sequencing supplies across transcriptomic research and drug development workflows.
- Drug discovery and development held a 59.08% application share in 2026, supported by RNA sequencing's role in gene expression analysis, disease mechanism investigation, biomarker discovery, and therapeutic target identification.
Market Expansion Drivers
- Increasing use of NGS in RNA-sequencing for research and diagnostics.
- Technological advancements in high-throughput RNA-sequencing platforms.
- Expansion of genomics research infrastructure in emerging markets.
Leading Market Participants
- Prominent players in the NGS-based RNA-sequencing market include Illumina (USA), Thermo Fisher Scientific (USA), QIAGEN (Netherlands), PacBio (USA), Oxford Nanopore Technologies (UK), BGI Genomics (China), Roche (Switzerland), Agilent Technologies (USA), Bio-Rad (USA), Takara Bio (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 5.16 billion
- 2027 Estimated Market Size: USD 5.96 billion
- Projected Market Size: USD 26.98 billion by 2036
- Growth Forecast: 17.99% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Product & Service (Consumables) | Application (Drug Discovery & Development) | End Use (Pharmaceutical & Biotechnology Companies) | Workflow (Sequencing)
- Emerging Opportunity Segment: Product & Service (Consumables) | Application (Drug Discovery & Development) | End Use (Pharmaceutical & Biotechnology Companies) | Workflow (Sequencing)
Market Growth Drivers and Industry Trends
Increasing use of NGS in RNA-sequencing for research and diagnostics
The growing use of next-generation sequencing for transcriptome analysis is driving demand for NGS-based RNA-sequencing technologies across research and diagnostic applications. Researchers are increasingly using RNA sequencing to characterize gene expression, identify novel transcripts, investigate disease mechanisms, and understand molecular responses to treatment. The ability to generate comprehensive transcriptomic profiles is also supporting the development of precision medicine and advanced molecular diagnostics.
Technological advancements in high-throughput RNA-sequencing platforms
Continuous improvements in sequencing chemistry, library preparation, automation, and data analysis are enhancing the performance of high-throughput RNA-sequencing platforms. These advancements are enabling researchers to process complex samples more efficiently while improving transcript detection, data quality, and workflow reproducibility. Increasingly streamlined sequencing workflows are making RNA-sequencing more accessible to laboratories conducting large-scale genomics and translational research.
Expansion of genomics research infrastructure in emerging markets
The development of genomics research infrastructure in emerging markets is supporting broader adoption of NGS-based RNA-sequencing technologies. Investments in sequencing laboratories, bioinformatics capabilities, research institutions, and specialized scientific training are strengthening the capacity to conduct advanced transcriptomic studies. As regional healthcare and research systems increasingly incorporate genomic approaches, demand for RNA-sequencing solutions is expected to expand across academic, clinical, and biotechnology applications.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing use of NGS in RNA-sequencing for research and diagnostics | 7% | Short term (≤ 2 yrs) | North America; Europe; Spillover: Asia Pacific | Medium | Fast |
| Technological advancements in high-throughput RNA-sequencing platforms | 6% | Medium term (2–5 yrs) | North America; Europe; Spillover: Asia Pacific | Low | Moderate |
| Expansion of genomics research infrastructure in emerging markets | 5% | Long term (5+ yrs) | Asia Pacific; Latin America; Spillover: MEA | Medium | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
The NGS-based RNA-sequencing market in North America accounted for a 51.06% share in 2026, supported by advanced sequencing infrastructure, extensive genomics research, and strong adoption of transcriptomic technologies across academic, pharmaceutical, and healthcare applications. The region benefits from a mature research ecosystem that increasingly uses RNA sequencing to investigate gene expression, disease mechanisms, biomarkers, and therapeutic responses. Growing emphasis on precision medicine is further increasing demand for high-resolution transcriptomic analysis, while advances in sequencing platforms, data analytics, and bioinformatics are improving the ability to process and interpret complex RNA datasets. Increasing research into cancer, rare diseases, immunology, and other molecular disorders is also creating broader opportunities for RNA-sequencing technologies. In addition, continued investment in life sciences research and the expansion of genomic medicine are supporting the integration of NGS-based RNA sequencing into both research and emerging clinical applications.
Asia Pacific (Fastest-Growing Region)
The NGS-based RNA-sequencing market in Asia Pacific is expanding rapidly due to increasing investments in genomics, improving sequencing infrastructure, and growing adoption of advanced molecular research technologies. The region is witnessing greater interest in transcriptomic studies for cancer research, drug discovery, disease profiling, and biomarker identification, creating broader applications for RNA sequencing. Expanding biotechnology and pharmaceutical research is also supporting demand for high-throughput sequencing technologies, particularly as organizations seek deeper insights into gene expression and molecular pathways. Improvements in laboratory capabilities, increasing availability of sequencing services, and growing awareness of precision medicine are helping broaden the use of RNA-sequencing approaches. Government-supported genomics initiatives and expanding research collaborations are further strengthening regional capabilities, while advances in bioinformatics and data analysis are making complex RNA datasets increasingly accessible to researchers.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Translational Genomics HubThe U.S. market is shaped by strong adoption of RNA-sequencing across biomedical research, precision medicine, and biopharma workflows. Near-term priorities center on higher-throughput platforms, clinical-grade workflows, multi-omics integration, and scalable bioinformatics capable of converting complex transcriptomic data into actionable research insights.
Germany 🇩🇪
Precision Research IntegrationGermany is prioritizing RNA-sequencing within molecular diagnostics, academic research, and pharmaceutical development, with emphasis on reproducible workflows and data quality. Demand is likely to favor integrated sequencing and analysis solutions that support translational research while fitting established laboratory infrastructure and regulatory expectations.
Japan 🇯🇵
Advanced Molecular ProfilingJapan's RNA-sequencing demand is closely linked to genomics research, oncology, drug discovery, and increasingly sophisticated molecular profiling. Market priorities include reliable sequencing performance, automation, and bioinformatics capabilities that can support detailed transcript analysis while improving workflow efficiency across research and clinical-development settings.
South Korea 🇰🇷
Biopharma Genomics ExpansionSouth Korea is strengthening RNA-sequencing use across biotechnology, pharmaceutical R&D, and precision-medicine research. Commercial priorities include accessible high-performance sequencing, streamlined sample-to-result workflows, and analytical platforms that help local biopharma and research organizations translate transcriptomic data into drug-development and biomarker applications.
France 🇫🇷
Public-Private Genomics AdoptionFrance is applying RNA-sequencing across academic genomics, oncology research, and pharmaceutical development, supported by expanding interest in precision medicine. Near-term priorities include interoperable sequencing workflows, advanced bioinformatics, and solutions that facilitate movement from research datasets toward validated translational and clinical applications.
Italy 🇮🇹
Research-Led Sequencing AdoptionItaly's RNA-sequencing market is supported by applications in biomedical research, oncology, rare diseases, and molecular studies. Buyers are likely to prioritize cost-efficient sequencing access, dependable analytical pipelines, and flexible platforms that enable research institutions and healthcare-linked laboratories to broaden transcriptomic capabilities without excessive workflow complexity.
NGS-based RNA-sequencing Market Share (%), by Product & Service, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct & Service Segment Analysis: Consumables (Largest & Fastest-Growing Segment)
In 2026, the consumables segment accounted for a 59.86% share of the product & service segment, reflecting the recurring requirement for reagents, library preparation materials, sequencing-related supplies, and other consumable components throughout NGS-based RNA-sequencing workflows. Unlike reusable sequencing infrastructure, consumables are required repeatedly as samples are processed, creating sustained demand across research and laboratory applications. Increasing adoption of RNA sequencing for transcriptomic analysis, gene expression profiling, biomarker discovery, and molecular research is expanding the volume of sequencing workflows and consequently increasing consumption of associated laboratory materials. Advances in sequencing protocols and the growing complexity of transcriptomic studies are also encouraging researchers to use specialized consumables designed to improve sample quality, workflow efficiency, and data reliability. As RNA-sequencing applications continue to expand across research and drug development, the consumables segment is positioned as both the largest and fastest-growing product & service category.
Application Segment Analysis: Drug Discovery & Development (Largest & Fastest-Growing Segment)
The drug discovery & development segment accounted for a 59.08% share of the application segment in 2026, supported by the growing use of NGS-based RNA sequencing to investigate gene expression, understand biological pathways, identify disease mechanisms, and evaluate potential therapeutic targets. RNA sequencing provides researchers with detailed information about transcriptomic changes, enabling deeper investigation of how genes respond to diseases, compounds, and therapeutic interventions. Its ability to support biomarker discovery and characterization of molecular responses is particularly valuable in increasingly data-driven drug development workflows. Pharmaceutical and biotechnology researchers are also using transcriptomic information to improve target identification, understand drug mechanisms, and support more precise therapeutic development. Continued advances in sequencing technologies, bioinformatics, and molecular analysis are expanding the range of drug research applications, supporting the segment's position as both the largest and fastest-growing application category.
End Use Segment Analysis: Pharmaceutical & Biotechnology Companies (Largest & Fastest-Growing Segment)
The pharmaceutical & biotechnology companies segment accounted for a 39.57% share of the end use segment in 2026, reflecting the increasing incorporation of NGS-based RNA sequencing into drug research, biomarker development, target validation, and molecular characterization. These organizations rely on transcriptomic data to understand biological processes and disease pathways, identify potential therapeutic targets, and evaluate molecular responses during drug development. The growing focus on precision medicine and targeted therapies is further increasing demand for technologies capable of providing detailed information about gene expression and cellular activity. Improvements in sequencing efficiency and data analysis are making RNA-sequencing workflows increasingly useful across different stages of pharmaceutical research, from early discovery through translational studies. As pharmaceutical and biotechnology companies continue to expand genomics-driven research and develop more personalized therapeutic approaches, this end-use segment is expected to maintain strong momentum as both the largest and fastest-growing category.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product & Service | Consumables, Instruments, Service | Consumables | Consumables |
| Application | Drug Discovery & Development, Clinical Diagnostics, Others | Drug Discovery & Development | Drug Discovery & Development |
| End Use | Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others | Pharmaceutical & Biotechnology Companies | Pharmaceutical & Biotechnology Companies |
| Workflow | Pre-sequencing, Sequencing, Data Analysis | Sequencing | Sequencing |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Growth in the NGS-based RNA-sequencing space is fueled by advances in library preparation that resolve complex transcriptomic architectures from difficult sample inputs. Automated prep workflows minimize manual variability and streamline high-volume operations, while low-input processing methodologies preserve transcript fidelity from scarce clinical biopsies without introducing severe amplification bias. To extract meaningful biological insights, vendors must align transcriptome depth and read-length strategies to deliver accurate isoform resolution without creating cost barriers. Furthermore, market leadership increasingly shifts toward integrated bioinformatics pipelines, where transparent, scalable data analytics transform raw reads into highly reproducible measurements across diverse experimental designs.
Top players in the NGS-based RNA-sequencing market:
- Illumina (USA)
- Thermo Fisher Scientific (USA)
- QIAGEN (Netherlands)
- PacBio (USA)
- Oxford Nanopore Technologies (UK)
- BGI Genomics (China)
- Roche (Switzerland)
- Agilent Technologies (USA)
- Bio-Rad (USA)
- Takara Bio (Japan)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Illumina (USA) | |||||||
| Thermo Fisher Scientific (USA) | |||||||
| QIAGEN (Netherlands) | |||||||
| PacBio (USA) | |||||||
| Oxford Nanopore Technologies (UK) | |||||||
| BGI Genomics (China) | |||||||
| Roche (Switzerland) | |||||||
| Agilent Technologies (USA) | |||||||
| Bio-Rad (USA) | |||||||
| Takara Bio (Japan) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| SeqOne Genomics | April 2025 | SeqOne Genomics acquired Life & Soft to expand its bioinformatics and multi-omics capabilities. The transaction integrates an ISO-certified sequencing platform and proprietary data analysis software, strengthening SeqOne's competitive positioning in the next-generation sequencing diagnostics market. |
| DNAnexus, Inc. | March 2025 | DNAnexus entered a strategic partnership with Alida Biosciences to advance epitranscriptomics research. The collaboration integrates Alida Biosciences' EpiScout Analysis Suite onto the DNAnexus cloud platform, enabling scalable data analysis and visualization for RNA modification and gene expression studies. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
NGS-based RNA-sequencing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood, Tissue, Cell & Cell Culture, Biofluids, FFPE Samples |
| RNA Target Type | Whole Transcriptome, mRNA, Small RNA, Targeted RNA Panels |
| Sequencing Technology | Sequencing by Synthesis, Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing |
NGS-based RNA-sequencing Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Clinical Adoption Roadmap |
|
| Multi-Omics Integration Opportunities |
|
| Biopharma Drug Discovery Applications |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the overall size of the NGS-based RNA-sequencing market?
What are the growth projections for the NGS-based RNA-sequencing industry?
How are precision medicine and transcriptomic research accelerating demand for NGS-based RNA-sequencing?
How are sequencing technology improvements and genomics infrastructure expansion influencing RNA-sequencing adoption?
Why do consumables dominate the NGS-based RNA-sequencing market?
How is drug discovery and development driving demand for RNA sequencing?
Why does North America dominate the NGS-based RNA-sequencing market?
How is Asia Pacific expanding its presence in the NGS-based RNA-sequencing market?
Which companies dominate the NGS-based RNA-sequencing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook